Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Unipolar Major Depressive Disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Unipolar Major Depressive Disorder. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-006510-36 Sponsor Protocol Number: NL79264.091.21 Start Date*: 2021-12-21
    Sponsor Name:Radboudumc
    Full Title: Exploring the Pharmacomicrobiomics of Depression
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001172-41 Sponsor Protocol Number: ITI-007-503 Start Date*: 2022-01-13
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) BG (Completed) PL (Completed) SE (Completed) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004023-24 Sponsor Protocol Number: PRETEC-EPO Start Date*: 2016-12-15
    Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet
    Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO)
    Medical condition: Bipolar disorder and unipolar depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004030-28 Sponsor Protocol Number: EKFADHTC01032017 Start Date*: 2018-09-10
    Sponsor Name:Psychiatric Research Unit
    Full Title: Cognition and weight gain during antidepressant treatment.
    Medical condition: Major Depressive Disorder.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012375 Depressed mood disorders and disturbances HLGT
    20.0 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    20.0 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    20.0 10037175 - Psychiatric disorders 10025467 Major depressive disorder, single episode, moderate degree LLT
    20.0 10037175 - Psychiatric disorders 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    20.0 10037175 - Psychiatric disorders 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    20.0 10037175 - Psychiatric disorders 10025463 Major depressive disorder, single episode LLT
    20.0 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    20.0 10037175 - Psychiatric disorders 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    20.0 10037175 - Psychiatric disorders 10025456 Major depressive disorder, recurrent episode, in partial or unspecified remission LLT
    20.0 10037175 - Psychiatric disorders 10067465 Major depressive disorder aggravated LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001192-17 Sponsor Protocol Number: ITI-007-501 Start Date*: 2021-11-24
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BG (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001212-29 Sponsor Protocol Number: ITI-007-502 Start Date*: 2022-01-23
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000090-23 Sponsor Protocol Number: UoB1651 Start Date*: 2013-06-19
    Sponsor Name:University of Bristol
    Full Title: Mirtazapine added to SSRIs for treatment resistant depression in primary care: a placebo controlled randomised controlled trial
    Medical condition: Treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10045543 Unipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004291-18 Sponsor Protocol Number: 54135419TRD4010 Start Date*: 2021-04-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013
    Medical condition: Treatment-Resistant Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) FI (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002106-36 Sponsor Protocol Number: JNJ-DEP Start Date*: 2016-01-11
    Sponsor Name:Clinirx Tangent Research
    Full Title: The effects of JNJ-39393406 on psychometric performance and residual depressive symptoms in 80 patients with unipolar or bipolar depression: a phase II exploratory add-on double blind placebo contr...
    Medical condition: Unipolar and bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004873 10004936 Bipolar depression LLT
    19.0 100000004873 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2020-000784-23 Sponsor Protocol Number: KKS-276 Start Date*: 2020-11-17
    Sponsor Name:Philipps-Universität Marburg
    Full Title: The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect)
    Medical condition: To unravel the neural correlates of the interaction between positive expectation (high/low) and single dose antidepressant treatment (verum/placebo) with esketamine in patients with major depressiv...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    21.1 10037175 - Psychiatric disorders 10081270 Major depressive disorder LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005007-12 Sponsor Protocol Number: 039(C)MD21046 Start Date*: 2023-02-17
    Sponsor Name:Angelini Pharma S.p.A.
    Full Title: Efficacy of Trazodone Once-a-Day for treatment of Major Depressive Disorder in patients with breast cancer.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004440-29 Sponsor Protocol Number: ITI-007-403 Start Date*: 2020-05-21
    Sponsor Name:Intra-Cellular Therapies, Inc. (ITI)
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes...
    Medical condition: Major depressive episodes (MDEs) associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) with mixed features or major depressive disorder (MDD) with mixed features
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10004936 Bipolar depression LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-000567-77 Sponsor Protocol Number: 42847922MDD1016 Start Date*: 2021-05-19
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have ...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA ES (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001637-27 Sponsor Protocol Number: LQD Start Date*: 2016-09-20
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
    Medical condition: Treatment resistant major depressive disorder (single episode or recurrent). Treatment resistant depression, defined as failure to respond to two or more adequate doses of antidepressant in the cur...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10067373 Depression perimenopausal LLT
    21.1 10037175 - Psychiatric disorders 10066555 Chronic depression LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012391 Depression postpartum (excl psychosis) LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10012390 Depression postoperative PT
    20.0 10037175 - Psychiatric disorders 10012386 Depression mental LLT
    21.1 10037175 - Psychiatric disorders 10066530 Acute depression LLT
    20.0 10037175 - Psychiatric disorders 10012389 Depression postmenopausal LLT
    20.0 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    21.1 10037175 - Psychiatric disorders 10037998 Reactive depression LLT
    21.1 10037175 - Psychiatric disorders 10042457 Suicidal depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003658-47 Sponsor Protocol Number: F02207 GE 3 03 Start Date*: 2006-11-21
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-011911-19 Sponsor Protocol Number: QUE/09 Start Date*: Information not available in EudraCT
    Sponsor Name:Ludwig-Maximilian-University of Munich, Department of Psychiatry
    Full Title: Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients
    Medical condition: In this study, patients suffering from unipolar depression are investigated. 40 unipolar depressed inpatients (age 18-65) enter the study after the procedure has been fully explained and written in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012378 Depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002404-34 Sponsor Protocol Number: F02695 LP 202 Start Date*: 2006-11-09
    Sponsor Name:Pierre Fabre Médicament
    Full Title: A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEP...
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) FI (Completed) CZ (Completed) SE (Completed) LV (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001209-26 Sponsor Protocol Number: 01032012 Start Date*: 2013-10-11
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in...
    Medical condition: Major Depression ICD10: F 32.1, F 32.2, F32.3, F33.1, F33.2, F33.3 Klassifikationscode MedDRA : 10012378
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005476-41 Sponsor Protocol Number: MMHSCT1096 Start Date*: 2012-05-18
    Sponsor Name:Manchester Mental Health and Social Care Trust
    Full Title: Ketamine augmentation of ECT to improve outcomes in depression
    Medical condition: Depressive disorder requiring treatment with electroconvulsive treatment (ECT)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000137-19 Sponsor Protocol Number: Start Date*: 2007-08-07
    Sponsor Name:Leiden University Medical Center
    Full Title: Metyrapone as additive treatment in patients with major depression
    Medical condition: unipolar depressive episode without psychotic features according to DSM-IV-TR
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027515 Metyrapone challenge test LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 07:03:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA